Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt ...
A large matched cohort study using U.S. electronic health records finds that patients with pityriasis rubra pilaris have significantly higher odds of leukemia and lymphoma than matched psoriasis ...
Krystal Biotech Inc. KRYS on Thursday released a clinical update for its intratumoral immunotherapy, KB113. The treatment ...
New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch ...
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease ...
Yale School of Medicine will jointly lead a new national research consortium focused on epidermal differentiation disorders, ...
A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
'I thought it was just me!' ...
Symptoms are often mistaken for irritation, thrush or an STI, delaying proper treatment. Campaigners say the taboo around ...
FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare ...
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results